Skip to main content
. 2016 Oct 28;11(10):e0164076. doi: 10.1371/journal.pone.0164076

Table 1. Baseline characteristics of patients according to proportion of time in therapeutic range.

TTR<65% (N = 5851; 58.9%) TTR≥65% (N = 4083; 41.1%) Total (N = 9934; 100%)
Age, mean (SD), years 70.7 (10.6) 71.9 (9.7) 71.2 (10.2)
Age group, n/N, %
 65–74 years 2029/5851 34.7 1430/4083 35.0 3459/9934 34.8
 ≥75 years 2343/5851 40.0 1786/4083 43.7 4129/9934 41.6
Women, n/N, % 2649/5851 45.3 1791/4083 43.9 4440/9934 44.7
BMI category, n/N, %
 <19 kg/m2 109/4594 2.4 40/3137 1.3 149/7731 1.9
 19–<25 kg/m2 1390/4594 30.3 771/3137 24.6 2161/7731 28.0
 25–<30 kg/m2 1715/4594 37.3 1245/3137 39.7 2960/7731 38.3
 30–<40 kg/m2 1214/4594 26.4 973/3137 31.0 2187/7731 28.3
 ≥40 kg/m2 166/4594 3.6 108/3137 3.4 274/7731 3.5
Medical history, n/N, %
 Congestive heart failure 1189/5851 20.3 673/4083 16.5 1862/9934 18.7
 History of hypertension 4574/5842 78.3 3283/4073 80.6 7857/9915 79.2
 Diabetes mellitus 1490/5851 25.5 888/4083 21.7 2378/9934 23.9
 Prior stroke/transient ischaemic attack 751/5851 12.8 583/4083 14.3 1334/9934 13.4
 Vascular disease* 814/5842 13.9 608/4077 14.9 1422/9919 14.3
 Chronic kidney disease (Grade ≥3) 749/5851 12.8 522/4083 12.8 1271/9934 12.8
 History of bleeding 121/5838 2.1 70/4077 1.7 191/9915 1.9
Alcohol consumption, n/N, %
 Abstinent 2585/4943 52.3 1544/3346 46.1 4129/8289 49.8
 Light 1701/4943 34.4 1427/3346 42.6 3128/8289 37.7
 Moderate 521/4943 10.5 323/3346 9.7 844/8289 10.2
 Heavy 136/4943 2.8 52/3346 1.6 188/8289 2.3
Smoker, n/N, %
 No 3329/5277 63.1 2332/3671 63.5 5661/8948 63.3
 Ex-smoker 1411/5277 26.7 1055/3671 28.7 2466/8948 27.6
 Current smoker 537/5277 10.2 284/3671 7.7 821/8948 9.2

*Peripheral artery disease or coronary artery disease with a history of acute coronary syndromes.

Renal function was assessed according to the National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative classification by investigators at baseline.

BMI, body mass index; SD, standard deviation; TTR, time in therapeutic range.